ARS Pharma entered into an exclusive licensing agreement with Abelló A/S (ALK) in November 2024, providing ALK with exclusive rights to commercialize neffy in Europe, Canada, United Kingdom, and certain other geographies outside of the United States. Under the terms of the agreement, ARS Pharma has received upfront and milestone payments and is eligible to receive additional regulatory and sales milestones. ARS Pharma will be responsible for manufacturing and supplying neffy to ALK in Canada and anticipates filing for approval of the 1 mg dose for children greater than 15 kg and less than 30 kg with Health Canada by this summer.
—Please visit https://ir.ars-pharma.com/news-releases/news-release-details/neffyr-epinephrine-nasal-spray-approved-canada-first-and-only for more information.